Glenmark Pharmaceuticals Ltd. and its subsidiary, Glenmark Pharmaceuticals Inc., USA, recently reached a settlement in ongoing antitrust and consumer protection lawsuits concerning generic Zetia® and Vytorin®, cholesterol treatment drugs. The lawsuits, consolidated in the Eastern District of Virginia, U.S., alleged that Glenmark entered an anticompetitive agreement in 2010 with Schering Corporation and MSP Singapore Company LLC, both part of Merck & Co., Inc.
Despite strongly disputing these claims, Glenmark settled with three plaintiff groups in 2023: Direct Purchaser Plaintiffs, Retailer Plaintiffs, and End-Payor Plaintiffs. However, four End-Payor Plaintiffs—Humana Inc., Centene Corporation, Kaiser Foundation Health Plan, Inc., and United Healthcare Services, Inc.—opted out, leading to separate litigation.
To resolve the dispute and eliminate uncertainties, Glenmark has agreed to a $7 million settlement with Humana, Centene, and Kaiser. The company maintains that the settlement does not imply any admission of wrongdoing or liability. Glenmark continues to focus on delivering high-quality pharmaceutical products while ensuring compliance with legal and regulatory standards.
